ArticleCancer cell2021
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
9.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 132 citations in OpenAlex.
- Trial
- Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.Nature communications · 2024Trial
- Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With AdvancedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Overcoming melanoma drug resistance: Mechanisms and clinical progress of oncolytic viruses combined with immune checkpoint inhibitors (Review).Oncology reports · 2026Review
- Regression-Associated Macrophages Recruit Natural Killer Cells That Constrain Targeted Therapy Resistance.Cancer research · 2026Article
- Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis.Journal of gastroenterology · 2026Article
- Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Clinical and experimental medicine · 2026Review
- Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.NPJ breast cancer · 2026Review
- A CD138+ tumor-associated macrophage/Siglec-F+ neutrophil feed-forward loop promotes immune evasion in pancreatic cancer.The Journal of clinical investigation · 2026Article
- The MEK1/2-IRF4 axis fosters T follicular helper cell differentiationand antitumor humoral immune response.Journal of translational medicine · 2026Article
- Hepatic arterial infusion chemotherapy (HAIC) combined with sequential or concurrent systemic targeted immunotherapy for advanced hepatocellular carcinoma: a single-center retrospective study.World journal of surgical oncology · 2026Review
- Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials.Molecular cancer · 2026Review
- Particulate matter 2.5 promotes bladder cancer cell migration and invasion through the crosstalk between integrin-mediated MAPK/ERK and Wnt/β-catenin pathways.Particle and fibre toxicology · 2026Article
- RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11bNature communications · 2026Article
- Tumor microbiome-transcriptome crosstalk identifiesTheranostics · 2026Article
- Targeting the MAPK Pathway in Cancer.International journal of molecular sciences · 2025Review
- Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal Cancer.International journal of molecular sciences · 2025Article
- Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors.Immunity · 2025Article
- Tumor desialylation surpasses anti-PD-L1 checkpoint therapy in restoring anti-tumor immunity in a murine model for colorectal cancer.International journal of cancer · 2025Article
- Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal Melanoma.Biomolecules · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 1 country.
Yujue WangDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Sixue LiuDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Zhentao YangDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Alain P AlgaziDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143, USA.
Shirley H LomeliDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Yan WangDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Megan OthusFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Aayoung HongDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Xiaoyan WangDivision of General Internal Medicine, Department of Medicine, University of California, Los Angeles, CA 90095, USA.
Chris E RandolphArkansas Children's Research Institute, Little Rock, AR 72202, USA.
Alexis M JonesHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Marcus W BosenbergDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Stephanie D ByrumDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Alan J TackettDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Henry LopezMuriGenics Inc, Vallejo, CA 94592, USA.
Clayton YatesDepartment of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USA.
David B SolitHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Antoni RibasDivision of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Marco PivaDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: mpiva@cicbiogune.es.
Gatien MoriceauDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: gmoriceau@mednet.ucla.edu.
Roger S LoDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: rlo@mednet.ucla.edu.
University of California, Los Angeles · USMemorial Sloan Kettering Cancer Center · USUniversity of Arkansas for Medical Sciences · USArkansas Children's Hospital · USCenter for Cancer Research · USFred Hutch Cancer Center · USUniversity of California, San Francisco · USYale University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MWomen's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MSWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2MTranslational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Samrat Roy Choudhury · 2017 to 2026
$27.6MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4MPreventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistanceR01CA176111 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROGER S LO · 2013 to 2026
$5.4MUnderstanding PD-L1/L2 protein regulation, detection and signaling to predict melanoma therapeutic sensitivityR21CA255837 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LO, ROGER S · 2021 to 2022
$397kExploiting Drug Addiction to Improve the Efficacy of MAPK Pathway Targeted Therapy in BRAF and NRAS Mutant MelanomaR21CA215910 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LO, ROGER S · 2018 to 2019
$367kNCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA176111NCI NIH HHS R21 CA215910NCI NIH HHS R21 CA255837NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009120NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888NIGMS NIH HHS P20 GM121293
Abstract
Rationally sequencing and combining PD-1/L1-and MAPK-targeted therapies may overcome innate and acquired resistance. Since increased clinical benefit of MAPK inhibitors (MAPKi) is associated with previous immune checkpoint therapy, we compare the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by Braf
Indexed as
AnimalsHumansImmune Checkpoint InhibitorsImmunotherapyMiceMitogen-Activated Protein Kinase KinasesNeoplasmsImmune Checkpoint InhibitorsMitogen-Activated Protein Kinase Kinasesanti-CTLA-4anti-PD-1/L1BRAF/NRAS/KRAS/NF1brain metastasiscolorectal carcinomaMAPK/BRAF/MEK inhibitor resistancemelanomapancreatic ductal adenocarcinomasequential-combination therapytumor immune microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.